NASDAQ:TXMD TherapeuticsMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.93 +0.01 (+0.10%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$9.92▼$9.9850-Day Range$2.07▼$12.2152-Week Range$1.99▼$62.50Volume635,159 shsAverage Volume656,055 shsMarket Capitalization$87.85 millionP/E RatioN/ADividend YieldN/APrice Target$187.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Stock Forecast (MarketRank)Overall MarketRank™1.66 out of 5 starsMedical Sector947th out of 1,432 stocksPharmaceutical Preparations Industry474th out of 685 stocksAnalyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.2 Analyst's Opinion Consensus RatingTherapeuticsMD has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $187.50, TherapeuticsMD has a forecasted upside of 1,788.2% from its current price of $9.93.Amount of Analyst CoverageTherapeuticsMD has only been the subject of 2 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesTherapeuticsMD has received 386 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTherapeuticsMD has received 183 “underperform” votes. (Add your “underperform” vote.)Community SentimentTherapeuticsMD has received 67.84% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote “Outperform” if you believe TXMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.80% of the stock of TherapeuticsMD is held by insiders.Percentage Held by InstitutionsOnly 33.91% of the stock of TherapeuticsMD is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TherapeuticsMD are expected to grow in the coming year, from ($7.51) to ($2.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TherapeuticsMD is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TherapeuticsMD is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About TherapeuticsMD (NASDAQ:TXMD)TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More TXMD Stock News HeadlinesJune 28, 2022 | marketwatch.comTherapeuticsMD Inc. stock remains steady Tuesday, still outperforms market - MarketWatchJune 24, 2022 | finance.yahoo.comSorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji - Yahoo FinanceJune 23, 2022 | marketwatch.comTherapeuticsMD Inc. stock rises Thursday, still underperforms market - MarketWatchJune 17, 2022 | americanbankingnews.comTherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Significant Increase in Short InterestJune 16, 2022 | seekingalpha.comTherapeuticsMD: Pushback Expected To Privatization Deal (NASDAQ:TXMD) - Seeking AlphaJune 13, 2022 | benzinga.com5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retail - BenzingaJune 10, 2022 | americanbankingnews.comTherapeuticsMD, Inc. Expected to Earn FY2023 Earnings of ($3.34) Per Share (NASDAQ:TXMD)June 8, 2022 | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Downgraded by HC Wainwright to "Neutral"June 7, 2022 | benzinga.comHC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target - Benzinga - BenzingaJune 7, 2022 | apnews.comSHAREHOLDER UPDATE: Halper Sadeh LLP Investigates VMW, TPTX, CTT, TXMDJune 6, 2022 | finance.yahoo.comEW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMDJune 2, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc. - Benzinga - BenzingaJune 2, 2022 | streetinsider.comTHERAPEUTICSMD ALERT: Bragar Eagel & Squire, PC Investigates Merger of TXMD and Encourages Investors to Contact the Firm - StreetInsider.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees416Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today6/29/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$187.50 High Stock Price Forecast$250.00 Low Stock Price Forecast$125.00 Forecasted Upside/Downside+1,788.2%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($21.690010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-172.41 million Net Margins-210.67% Pretax Margin-210.67% Return on EquityN/A Return on Assets-93.28% Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.28 Sales & Book Value Annual Sales$86.95 million Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value($11.05) per share Price / Book-0.90Miscellaneous Outstanding Shares8,847,000Free Float8,068,000Market Cap$87.85 million OptionableOptionable Beta2.10 TherapeuticsMD Frequently Asked Questions Should I buy or sell TherapeuticsMD stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TherapeuticsMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View analyst ratings for TherapeuticsMD or view top-rated stocks. What is TherapeuticsMD's stock price forecast for 2022? 3 Wall Street analysts have issued 12 month price targets for TherapeuticsMD's stock. Their TXMD stock forecasts range from $125.00 to $250.00. On average, they predict TherapeuticsMD's stock price to reach $187.50 in the next twelve months. This suggests a possible upside of 1,788.2% from the stock's current price. View analysts' price targets for TherapeuticsMD or view top-rated stocks among Wall Street analysts. How has TherapeuticsMD's stock performed in 2022? TherapeuticsMD's stock was trading at $17.7750 on January 1st, 2022. Since then, TXMD shares have decreased by 44.1% and is now trading at $9.93. View the best growth stocks for 2022 here. When is TherapeuticsMD's next earnings date? TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for TherapeuticsMD. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings data on Monday, May, 16th. The company reported ($5.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.50) by $2.19. During the same quarter in the previous year, the company earned ($5.50) EPS. View TherapeuticsMD's earnings history. When did TherapeuticsMD's stock split? How did TherapeuticsMD's stock split work? TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of TherapeuticsMD stock prior to the reverse split would have 2 shares after the split. Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the following people: Mr. Hugh O'Dowd M.B.A., Pres, CEO & Director (Age 56, Pay $1.19M)Mr. Robert G. Finizio, Co-Founder (Age 51, Pay $2.53M) (LinkedIn Profile)Mr. Marlan D. Walker J.D., Gen. Counsel & Secretay (Age 47, Pay $506.21k)Mr. John C. K. Milligan IV, Chief Exec. Officer of VitaCare Prescription Services (Age 60, Pay $606.1k)Dr. Brian A. Bernick F.A.C.O.G., M.D., Co-Founder and Chief Scientific & Medical Officer (Age 54)Mr. Michael C. Donegan, Interim CFO, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 54)Ms. Daniella Silva, Chief Compliance Officer (Age 36)Mr. Benjamin Foulk, VP of HR (Age 52)Mr. Mitchell L. Krassan, Exec. VP and Chief Strategy & Performance Officer (Age 56)Ms. Julia M. Amadio, Chief Product Officer Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include Affimed (AFMD), Khosla Ventures Acquisition (KVSA), Dyne Therapeutics (DYN), Tyra Biosciences (TYRA), Akero Therapeutics (AKRO), Lexicon Pharmaceuticals (LXRX), Biomea Fusion (BMEA), ALX Oncology (ALXO), Phathom Pharmaceuticals (PHAT), Heron Therapeutics (HRTX), PyroGenesis Canada (PYR), DiaMedica Therapeutics (DMCAF), Zymeworks (ZYME), OptiNose (OPTN) and Regulus Therapeutics (RGLS). View all of TXMD's competitors. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU). What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $9.93. How much money does TherapeuticsMD make? TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $87.85 million and generates $86.95 million in revenue each year. The company earns $-172.41 million in net income (profit) each year or ($21.690010) on an earnings per share basis. How many employees does TherapeuticsMD have? TherapeuticsMD employs 416 workers across the globe. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for TherapeuticsMD is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at [email protected], or via fax at 561-431-3389. This page (NASDAQ:TXMD) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here